Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
PharmAla launches its Phenesafe AI, a custom-made technology stack allowing it to easily discover new MDMA-like molecules
-
PharmAla releases Q2 financial statements showing increased customer deposits, shipments
-
PharmAla sidesteps tariff risk and expands clinical operations in the United States by contracting with Sharp Clinical Services as distribution partner
-
PharmAla completes shipment of MDMA to University of Washington, to be used in a Narcissism clinical trial. It also appoints Ali Taghva as CCO.
-
PharmAla opens the European Market for MDMA, signs Duchefa Farma as its first national-level distributor for LaNeo MDMA in Europe
-
PharmAla completes historic first shipment of MDMA from Canada to USA for use in a UCLA Clinical Trial
-
PharmAla to supply the STRONG STAR Consortium with new 20mg MDMA dose to treat active-duty military personnel in a clinical trial
-
PharmAla adds Matthew Azrieli to Advisory Team
-
PharmAla releases its Q1 financial statements
-
PharmAla partners with Merhavim and MAPS Israel for innovative MDMA PTSD clinical trial data sharing partnership in wake of Gaza Ceasefire